Drug delivery system

Abstract

The utility model provides an easy-to-fix and easy-to-disassemble drug delivery system, comprising: a liquid collection port for collecting a liquid medicine; the dosing tube is provided with a subcutaneous head end and a positioning tail end, the subcutaneous head end is fixedly connected with the liquid collection port in an inserted mode, the positioning tail end is used for being positioned at a target position, and the dosing tube is used for conveying liquid medicine to the target position; the positioning tip is configured to define a transitional proximal portion and a curled distal portion shaped to be helically wound about a first reference line to form a bump after passing through the transitional proximal portion; the drug delivery system further comprises a tube taking device and a sheath tube, and the tube taking device is provided with a pagoda head end and used for being connected with the subcutaneous head end. The sheath tube is nested outside the tube taking device and the administration tube from one side, far away from the subcutaneous head end, of the tube taking device, and is used for stripping the administration tube and the subcutaneous tissue and / or the inner wall of a blood vessel; the sheath tube and the tube taking device are used for detaching the drug delivery system in a non-destructive mode. The drug delivery system can be conveniently fixed in the blood vessel, and the inner wall of the blood vessel and subcutaneous tissue are not prone to being damaged when the drug delivery system is dismantled.

Description

Technical Field

[0001] The present application relates to the field of medical devices, and in particular to a drug delivery system. Background Art

[0002] The decompensated stage of cirrhosis is often characterized by portal hypertension and liver function damage, and is often complicated by symptoms such as hepatic encephalopathy, gastrointestinal bleeding, and sepsis. Early cirrhosis or liver fibrosis can be reversed through drug treatment. Currently, the commonly used route of treatment is basically peripheral vein, which can improve liver function to a certain extent, promote liver cell regeneration, and delay the progression of cirrhosis. However, patients with cirrhosis have liver microcirculation disorders and portal vein hemodynamic abnormalities. Conventional peripheral vein application of liver drugs is difficult to fully exert the drug effect, and the effective utilization rate is low. Therefore, how to achieve targeted drug delivery to the liver is a clinical trend in the study of the treatment of cirrhosis or liver fibrosis.

[0003] For the liver organ, the portal vein is the main functional blood vessel of the liver, supplying 75% of the liver's blood. The hepatic sinusoids are directly connected to the small branches of the portal vein. Hepatocytes take in nutrients and exchange substances in the hepatic sinusoids. Therefore, for targeted drug delivery, the most important thing is to establish a portal vein drug delivery channel, directly introduce the drug into the portal vein system, so that it can directly act on the hepatocytes and intercellular matrix, and give full play to the therapeutic effect of the drug on liver fibrosis and cirrhosis.

[0004] Clinically, a portal vein medication channel can be established through minimally invasive means, but direct percutaneous portal vein catheterization will damage the liver capsule. For cirrhotic patients with a large amount of peritoneal effusion and severe coagulation dysfunction, the risk of intraperitoneal bleeding is very high; at the same time, after percutaneous portal vein catheterization, when the patient is active or affected by respiratory movement, the indwelling catheter is easy to fall off and gradually move outward or even fall off into the abdominal cavity. Once the indwelling catheter is found to be off, it needs to be repositioned or even re-catheterized. Therefore, the present application adopts a jugular vein approach and establishes a portal vein medication channel through jugular vein puncture, which not only does not damage the liver capsule, but also adopts a unique drug delivery system design in the scheme of the present application, so that the drug delivery tube can be firmly fixed at the portal vein position under the premise of satisfying portal vein blood circulation, so that it is not easy to shift or peel off, etc., which is convenient for drug delivery; in addition, the present application can also realize the removal of the drug delivery tube from the portal vein position without damaging the blood vessel wall to realize the disassembly of the drug delivery system. Utility Model Content

[0005] The present application mainly provides a drug delivery system, the design of which can accurately deliver drugs to targeted organs, improve the accuracy of drug delivery, reduce drug loss during systemic blood circulation, increase local drug concentration, and after being positioned at the target position, it can be fixed at the target position and is not prone to displacement. After the drug delivery is completed, the drug delivery system can be easily removed from the target position, thereby improving the utilization rate and efficiency of clinical surgery.

[0006] In order to solve the above technical problems, the technical solution adopted in the present application is: to provide a drug delivery system that is easy to fix and disassemble, including: a liquid collection port for collecting liquid medicine; a drug delivery tube, having a subcutaneous head end and a positioning end, the subcutaneous head end is fixedly plugged into the liquid collection port, the positioning end is used to be positioned at the target position, and the drug delivery tube is used to transport the drug solution to the target position; the positioning end is configured to define a proximal part of the transition and a curled distal part, and the curled distal part is formed to be spirally wound around a first reference line after passing through the proximal part of the transition to form a bulge; the drug delivery system also includes a tube remover and a sheath, the tube remover has a pagoda head end for connecting with the subcutaneous head end; the sheath is sequentially nested in the tube remover and the outside of the drug delivery tube from the side of the tube remover away from the subcutaneous head end, for peeling off the drug delivery tube and subcutaneous tissue and / or the inner wall of the blood vessel; the sheath and the tube remover are used to disassemble the drug delivery system in a non-destructive manner.

[0007] In one embodiment, the positioning end is configured such that when the drug delivery tube enters the blood vessel along the guide wire and is positioned at the target position, the raised portion abuts against the inner wall of the blood vessel at the target position to fix the drug delivery system.

[0008] In one embodiment, the positioning end is configured with a flexible shape memory material for allowing the guide wire to enter the drug delivery tube to the positioning end, and the raised portion is configured to match the shape of the guide wire; and the positioning end restores the shape of the raised portion after the guide wire is removed.

[0009] In one embodiment, the drug delivery system further comprises an atraumatic needle, which is used for atraumatic puncture and delivery of the drug solution to the collection port.

[0010] In one embodiment, the sheath is a tearable sheath.

[0011] In one embodiment, the drug delivery system includes a snap-on connection ring, one end of which is connected to the liquid collection port and the other end is connected to the drug delivery tube.

[0012] In one embodiment, the liquid collection port has a liquid collection hole, a connector, a puncture septum and a shell. The liquid collection hole is fluidically connected to the connector and is connected to the drug delivery tube through the connector. The shell accommodates the liquid collection hole, and the puncture septum covers the liquid collection hole for non-destructive needle puncture drug delivery.

[0013] In one embodiment, the drug delivery system is placed into the human body via the jugular vein, the fluid collection port is placed subcutaneously, and the positioning end of the drug delivery tube is positioned in the portal vein and against the side wall of the portal vein.

[0014] In one embodiment, the drug delivery system is delivered to the portal vein via a puncture system, which includes a guide wire, a puncture needle, a puncture catheter, a guide, a guide sleeve, an outer sheath, an outer sheath core, and a dilator.

[0015] In one embodiment, both the inner and outer lumens of the drug delivery tube are provided with an anticoagulant coating and the drug delivery tube is visible under X-ray.

[0016] The beneficial effects of the present application are as follows: in the drug delivery system of the present application, the positioning end design makes it easy for the drug delivery tube to be transported to the target position, and after being positioned at the target position, the positioning end restores the shape of the raised portion, and the raised portion abuts against both sides of the inner wall of the blood vessel at the target position, fixing the drug delivery tube so that it is not easy to fall off; at the same time, after the drug delivery operation is completed, the drug delivery tube can be easily removed from the target position without damaging the inner wall of the blood vessel and the subcutaneous tissue. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the following briefly introduces the drawings required for the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work. Among them:

[0018] Figure 1 This is a schematic structural diagram of an embodiment of a drug delivery system in this application;

[0019] Figure 2a This is a schematic structural diagram of an embodiment of a drug delivery tube in the present application;

[0020] Figure 2b A cross-sectional view of an embodiment of a raised portion of a drug delivery tube in the present application;

[0021] Figure 3a (1) is a schematic diagram of the structure of an embodiment of the present application before the liquid collection port and the drug delivery tube are assembled, and (2) is a schematic diagram of the structure of an embodiment of the present application after the liquid collection port and the drug delivery tube are assembled;

[0022] Figure 3b This is a schematic cross-sectional structure diagram of an implementation method of a liquid collection port in this application;

[0023] Figure 3c This is a schematic diagram from one perspective of an implementation method of a liquid collection port in this application;

[0024] Figure 4This is a partial enlargement of the liquid collection port joint in this application Figure 1 A cross-sectional view of an embodiment;

[0025] Figure 5a It is a cross-sectional view of a structural schematic diagram of an embodiment of a snap-on connecting ring in the present application;

[0026] Figure 5b A cross-sectional view of an embodiment of a snap-on connecting ring in the present application;

[0027] Figure 6 This is a structural schematic diagram of an implementation method of a tube extractor in this application;

[0028] Figure 7 This is a schematic structural diagram of an embodiment of the sheath tube in the present application;

[0029] Explanation of the reference numerals: 10. drug delivery system; 1. liquid collection port; 11. connector; 12. liquid collection hole; 13. puncture septum; 14. shell; 15. suture hole; 2. drug delivery tube; 21. subcutaneous head end; 22. positioning end; 221. proximal part; 222. raised part; 223. first reference line; 3. tube remover; 31. pyramid head end; 4. sheath; 5. snap-on connecting ring; 51. body; 52. stress tube. DETAILED DESCRIPTION

[0030] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by technicians in the technical field to which this application belongs; the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit this application; the terms "including" and "having" in the specification and claims of this application and the above-mentioned figure descriptions and any variations thereof are intended to cover non-exclusive inclusions.

[0032] In the description of the embodiments of the present application, the technical terms "first", "second", etc. are only used to distinguish different objects, and cannot be understood as indicating or implying relative importance or implicitly indicating the number, specific order or primary and secondary relationship of the indicated technical features. In the description of the embodiments of the present application, the meaning of "multiple" is more than two, unless otherwise clearly and specifically defined.

[0033] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.

[0034] In the description of the embodiments of the present application, unless otherwise clearly specified and limited, technical terms such as "installed", "connected", "connected", "fixed" and the like should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral one. For ordinary technicians in this field, the specific meanings of the above terms in the embodiments of the present application can be understood according to specific circumstances.

[0035] In the scheme of the present application, it is necessary to establish a portal vein medication channel in advance through the Tips procedure. Tips is an important means of treating portal hypertension. It is a trans-jugular vein approach from the hepatic vein to the portal vein, and then a stent is implanted to maintain the patency of the channel, thereby establishing a hepatic vein-portal vein shunt channel to achieve the purpose of reducing portal hypertension. For some patients who need portal vein medication, the Tips procedure can be used to establish a portal vein channel, and then combined with an intravenous drug delivery device to achieve targeted portal vein drug delivery.

[0036] See also Figure 1 - Figure 3, the present application provides a drug delivery system 10 that is easy to fix and disassemble. In some applications, the drug delivery system 10 is suitable for portal vein drug delivery. The drug delivery system 10 includes a liquid collection port 1 for collecting liquid medicine; a drug delivery tube 2, having a subcutaneous head end 21 and a positioning end 22, the subcutaneous head end 21 is fixedly plugged with the liquid collection port 1, the positioning end 22 is used to be positioned at a target position, and the drug delivery tube 2 is used to transport the liquid medicine to the target position; after the operator infuses the liquid medicine into the liquid collection port 1, the liquid medicine can flow from the liquid collection port 1 to the target position through the drug delivery tube 2; the positioning end 22 is configured to define a transitional proximal portion 221 and a curled distal portion, and the curled distal portion is formed to be spirally wound around a first reference line 223 after passing through the transitional proximal portion 221 to form a raised portion 222.

[0037] See Figure 2- Figure 4In some applications of the present application, the liquid collection port 1 is placed under the patient's skin and connected to the subcutaneous head end 21 of the drug delivery tube 2. In one embodiment, the liquid collection port 1 has a joint 11, and the joint 11 is a truncated cone structure. The diameter of the truncated cone of the joint 11 on the side close to the drug delivery tube 2 is smaller; the diameter of the truncated cone of the joint 11 on the other side away from the drug delivery tube 2 is larger. When the subcutaneous head end 21 of the drug delivery tube 2 is plugged into the joint 11 of the liquid collection port 1, the drug delivery tube 2 slides from the side of the truncated cone with a smaller diameter to the side of the truncated cone with a larger diameter and is nested on the outside of the joint 11. The structural design of the truncated cone can facilitate the operator to nest the drug delivery tube 2 and the joint 11. After the nesting is completed, the drug delivery tube 2 is not easy to slip off the joint 11. Optionally, on the side of the truncated cone with a smaller diameter of the joint 11, a circular tube structure can be extended toward the drug delivery tube 2. The circular tube structure has the same diameter as the side of the truncated cone with a smaller diameter. More preferably, the diameter of the circular tube structure is not greater than the diameter of the subcutaneous head end 21 of the drug delivery tube 2. In another embodiment, the drug delivery system 10 may further include a snap-on connection ring 5, please continue to refer to Figures 3 and 5, the snap-on connection ring 5 is nested on the outside of the drug delivery tube 2, and when the drug delivery tube 2 and the connector 11 are nested, the snap-on connection ring 5 is moved to the nesting position of the connector 11 and the drug delivery tube 2, and the connector 11 and the drug delivery tube 2 are fixed to make them nested more tightly, and the drug delivery tube 2 is less likely to slip off the connector 11.

[0038] In one embodiment, the snap-on connection ring 5 includes a body 51 and a stress tube 52, see Figure 5a and Figure 5b As shown in FIG. 1 , the length of the snap-on connection ring 5 is recorded as L, and the inner diameter of the snap-on connection ring 5 is recorded as Φd. The left side of the snap-on connection ring 5 is used to connect to the liquid collection port 1 , and the right side is used to connect to the drug delivery tube 2 .

[0039] The positioning end 22 is configured to define a transitional proximal portion 221 and a curled distal portion, the curled distal portion forms a protuberance 222 after passing through the proximal portion 221, and the first reference line 223 defines the curling direction of the protuberance 222, that is, the protuberance 222 is curled and wound around the extension direction of the first reference line 223 to form the protuberance 222. When the first reference line 223 is parallel to the extension direction of the body of the dosing tube 2, the transverse plane formed by the protuberance 222 is perpendicular to the body of the dosing tube 2; when the first reference line 223 is at a certain angle to the extension direction of the body of the dosing tube 2, the transverse plane formed by the protuberance 222 is at a certain angle to the body of the dosing tube 2; specifically, it can be an acute angle or an obtuse angle. Preferably, in the embodiment of the present application, the first reference line 223 is parallel to the extension direction of the body of the dosing tube 2, that is, the extension direction of the body of the dosing tube 2 is perpendicular to the transverse plane formed by the protuberance 222, at which time, the effect of fixing the dosing tube 2 to the inner wall of the blood vessel is best.

[0040] See also Figure 2b, is a cross-sectional view of the raised portion 222. The raised portion 222 has an inner diameter d and an outer diameter D. The size of the outer diameter does not exceed the inner diameter of the target blood vessel. The outer side of the raised portion 222 with the largest diameter abuts against the inner wall of the blood vessel to prevent the positioning end 22 of the drug delivery tube 2 from moving or detaching during drug delivery, which affects the targeted drug delivery of the drug delivery system 10. The side of the positioning end 22 away from the subcutaneous head end 21 is an opening structure, which is used for the drug solution to flow out of the opening and act on the targeted target position.

[0041] In an embodiment of the present application, the drug delivery system 10 further comprises a non-destructive needle, the cross section of the needle opening of the non-destructive needle is parallel to the extension direction of the needle, so that the blade becomes a side hole, which reduces the generation of debris during the puncture process.

[0042] In one embodiment, the dosing tube 2 can be developed under X-rays. Specifically, a developing layer can be provided on the dosing tube 2, and the developing layer is doped in the tube material of the dosing tube 2. Alternatively, developing marking points are provided at equal intervals along the extension direction of the tube body of the dosing tube 2. The equally spaced developing marking points can mark the length of the dosing tube 2 for the convenience of clinical use. Preferably, the entire dosing tube 2 is developed.

[0043] In addition, in order to reduce the coagulation phenomenon caused by the flow of blood during the drug administration process and the drug administration tube 2, in the embodiment of the present application, the inner and outer cavities of the drug administration tube 2 are both provided with an anticoagulant coating to reduce the risk of thrombosis due to long-term implantation.

[0044] In a common implementation of removing the drug delivery system 10, the subcutaneous head end 21 of the drug delivery tube 2 is usually directly grasped and the drug delivery tube 2 is pulled out of the body. This implementation has many disadvantages. First, the part of the subcutaneous head end 21 of the drug delivery tube 2 that can be grasped is relatively short, which is not convenient for operation; second, the drug delivery tube 2 may be adhered to the subcutaneous tissue or the inner wall of the blood vessel, and such operation may damage the subcutaneous tissue or the inner wall of the blood vessel. Therefore, the drug delivery system 10 of the present application is additionally provided with a tube remover 3 and a sheath 4 structure to increase the operable length of the drug delivery system 10 for removal and reduce the damage to the patient's blood vessel wall caused by direct tube removal.

[0045] In the embodiment of the present application, the drug delivery system 10 further comprises a tube remover 3 and a sheath 4, see Figure 6 , Figure 7The tube remover 3 is a slender hollow structure that can smoothly pass through the inner cavity of the drug delivery tube 2. The end of the tube remover 3 is designed as a pagoda head structure, with a pagoda head end 31, which is used to connect with the subcutaneous head end 21 of the drug delivery tube 2, and can increase the operable length of the tube removal operation; the sheath tube 4 is a hollow structure, and the sheath tube 4 is nested in the tube remover 3 and the outside of the drug delivery tube 2 from the side of the tube remover 3 away from the subcutaneous head end 21, and is used to peel off the adhesion between the drug delivery tube 2 and the subcutaneous tissue and the blood vessel wall; preferably, the total length of the tube remover 3 and the drug delivery tube 2 is not less than the length of the sheath tube 4, and it is best that the total length of the tube remover 3 and the drug delivery tube 2 is greater than the length of the sheath tube 4, so as to better increase the operable length space. In a preferred embodiment, the sheath tube 4 is a tearable sheath to increase the convenience of operation, and the sheath tube 4 and the tube remover 3 are used to disassemble the drug delivery system 10 in a non-destructive manner. Specifically, when the drug delivery system 10 finishes the drug delivery work, the subcutaneous head end 21 of the drug delivery tube 2 is removed from the connector 11 of the liquid collection port 1 and connected to one end of the pagoda head end 31 of the tube remover 3. The pagoda head end 31 is provided to facilitate the drug delivery tube 2 to be nested in the outside of the tube remover 3 and not to slip off from the outside of the tube remover 3. After the guide wire enters the portal vein through the inner cavity of the tube remover 3 and the drug delivery tube 2, it is sent into the sheath tube 4 from the side of the tube remover 3 away from the subcutaneous head end 21 of the drug delivery tube 2. The tube remover 3 and the drug delivery tube 2 are both accommodated in the inner cavity of the sheath tube 4. The sheath tube 4 can be used to peel off the adhesion between the drug delivery tube 2 and the subcutaneous tissue or the blood vessel wall to reduce the damage to the inner wall of the blood vessel when removing the drug delivery tube 2. When the sheath tube 4 is used up, it can be removed by tearing.

[0046] In one application of the present application, the drug delivery system 10 enters the patient's blood vessel through the tips procedure. In the present application, the tips instruments involved include: an outer sheath, an outer sheath core, a puncture needle, a puncture catheter, a guide, a guide sleeve, a dilator, and a guide wire. The outer sheath contains the outer sheath core, and the guide contains the guide sleeve. The guide is used to adjust the puncture angle. In the implementation scheme of the present application, the guide has an adjustment range of 40°-70°. When the guide is positioned at a suitable position, it can be rotated to select the best angle within a reasonable angle range for hepato-portal vein puncture.

[0047] The method of using the drug delivery system 10 is: first perform a tips operation, and then establish a path for the drug delivery system 10. When the operator performs the tips operation, under the guidance of X-ray fluoroscopy, the guide wire is sent into the hepatic vein branch through the jugular vein approach, and the wound is expanded with a dilator to facilitate the subsequent instruments to enter the jugular vein through the wound; the outer sheath combined with the outer sheath core is sent into the hepatic vein along the path established by the guide wire, and the outer sheath core is withdrawn, and then the guide combined with the guide sleeve is introduced into the hepatic vein through the outer sheath and guide wire path, and the guide wire is withdrawn; the puncture needle and the puncture catheter are combined, and they are inserted into the inner cavity of the guide until they reach the hepatic vein position but do not extend out of the farthest end of the guide, and the guide can be adjusted by rotating the guide. After the distal end is pointed and the outer sheath is adjusted to the ideal position, the guide and guide sleeve are pushed forward until they are close to the wall of the hepatic vein. After the direction of the outer sheath is adjusted, the puncture needle and puncture catheter are pushed forward to puncture the liver to the portal vein and penetrate. After the penetration is completed, the puncture needle is withdrawn, the puncture catheter is retained, and a syringe loaded with contrast agent is connected to the proximal end of the puncture catheter. The syringe is withdrawn while the puncture catheter is withdrawn. When blood return is found in the syringe, it proves that the distal end of the puncture catheter is located in the portal vein; after observing the blood return of the portal vein, a small amount of contrast agent is injected to observe the morphology and distribution of the portal vein. The syringe is withdrawn to introduce the guide wire into the portal vein; keep the guide in place, push the outer sheath and puncture catheter into the portal vein, withdraw the guide and puncture catheter, and the channel is completed.

[0048] After the hepatic vein-portal vein shunt channel is established, the drug delivery tube 2 is inserted along the guide wire. The positioning end 22 of the drug delivery tube 2 is made of flexible material. After the guide wire is inserted into the inner cavity of the drug delivery tube 2, the shape of the positioning end 22 is adapted to the shape of the guide wire; after the drug delivery tube 2 is sent to the designated position of the portal vein, the guide wire and the outer sheath are withdrawn, and the positioning end 22 of the drug delivery tube 2 returns to its original shape.

[0049] Then, a subcutaneous pouch is opened near the jugular vein access point, and the pouch is used to hold the liquid collection port 1. Local infiltration anesthesia is performed on the path from the pouch to the jugular vein access point, and a subcutaneous tunnel from the jugular vein puncture point to the pouch is established along the anesthesia path using the tube extractor 3. The pagoda head end 31 of the tube extractor 3 is connected to the subcutaneous head end 21, and the subcutaneous head end 21 of the drug delivery tube 2 extends from the jugular vein puncture point to the pouch along the subcutaneous tunnel and is connected to the connector 11 of the liquid collection port 1, and the wound at the subcutaneous pouch is sutured to complete the implantation operation of the drug delivery system 10.

[0050] When the drug administration is completed, a small incision is made at the pouch, and the subcutaneous head end 21 of the drug administration tube 2 is removed from the connector 11 of the liquid collection port 1, and the subcutaneous head end 21 is connected to the pagoda head end 31 of the tube remover 3, and then the guide wire is extended into the inner cavity of the tube remover 3 and the drug administration tube 2 and reaches the portal vein position. At this time, due to the intervention of the guide wire, the shape of the positioning end 22 of the drug administration tube 2 will change to match the shape of the guide wire, and the sheath tube 4 is pushed along the outer wall of the tube remover 3 and the drug administration tube 2 into the subcutaneous tissue and the blood vessel. The sheath tube 4 can peel off the adhesion between the drug administration tube 2 and the subcutaneous tissue and the inner wall of the blood vessel to prevent damage to the subcutaneous tissue or the inner wall of the blood vessel during the disassembly of the drug administration tube 2. When the sheath tube 4 is pushed into place, the drug administration tube 2, the guide wire, and the sheath tube 4 can be removed in turn to complete the disassembly of the drug administration system 10.

[0051] In other embodiments, the liquid collecting port 1 further comprises a liquid collecting hole 12, a puncture partition 13 and a shell 14, see Figure 3b The liquid collecting hole 12 is in fluid communication with the connector 11 and delivers the drug solution to the drug delivery tube 2 through the connector 11. The outer shell 14 accommodates the liquid collecting hole 12 inside, and the puncture septum 13 covers the liquid collecting hole 12 for non-destructive needle puncture drug delivery. In particular, the puncture septum 13 is made of silicone material and has a certain elasticity, which can be used for non-destructive needle puncture 2500 times / cm2 without leakage, and due to the unique needle design of the non-destructive needle, no debris is generated during the puncture process. The liquid collecting hole 12 has good biocompatibility and can provide excellent puncture performance without the risk of being penetrated. The drug solution is in direct contact with the liquid collecting hole 12, which improves the durability of the liquid collecting port 1 and enables the liquid collecting port 1 to also have high-pressure injection resistance.

[0052] In other embodiments, the liquid collection port 1 further includes a suture hole 15, see Figure 3c The number of suture holes 15 is set to be no less than two, and can be three, four, etc., for suturing and fixing the liquid collecting port 1 to the skin when it is accommodated in the pouch, so as to prevent the liquid collecting port 1 from moving in the pouch. The positions of the suture holes 15 are arranged in a triangular shape to increase the suture stability. In other embodiments, the positions of the suture holes 15 are arranged in the positive direction, the long direction, or the circular direction to achieve the stabilizing effect of the present application, and no specific limitation is made here.

[0053] The above description is only an implementation method of the present application, and does not limit the patent scope of the present application. Any equivalent structure or equivalent process transformation made using the contents of the present application specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. A drug delivery system, comprising: A liquid collection port for collecting liquid medicine; A drug delivery tube having a subcutaneous head end and a positioning end, wherein the subcutaneous head end is fixedly plugged with the liquid collection port, the positioning end is used to be positioned at a target position, and the drug delivery tube is used to deliver the drug solution to the target position; characterized in that: The positioning tip is configured to define a transitional proximal portion and a curled distal portion, the curled distal portion being shaped to helically wrap around a first reference line to form a ridge after passing through the transitional proximal portion; The drug delivery system also includes a tube remover and a sheath, wherein the tube remover has a pagoda head end for connecting to the subcutaneous head end; the sheath is sequentially nested between the tube remover and the outside of the drug delivery tube from the side of the tube remover away from the subcutaneous head end, and is used to peel off the drug delivery tube and subcutaneous tissue and / or the inner wall of the blood vessel; the sheath and the tube remover are used to disassemble the drug delivery system in a non-destructive manner.

2. The drug delivery system according to claim 1, characterized in that: The positioning end is configured such that when the drug delivery tube enters the blood vessel along the guide wire and is positioned at the target position, the raised portion abuts against the inner wall of the blood vessel at the target position to fix the drug delivery system.

3. The drug delivery system according to claim 2, characterized in that: The positioning end is configured with a flexible shape memory material for allowing the guide wire to enter the drug delivery tube to the positioning end, and the raised portion is configured to match the shape of the guide wire; and after the guide wire is removed, the positioning end restores the shape of the raised portion.

4. The drug delivery system according to claim 1, characterized in that: The drug delivery system further comprises an atraumatic needle, which is used for atraumatic puncture and delivery of the drug solution to the liquid collection port.

5. The drug delivery system according to claim 1, characterized in that: The sheath tube is a tearable sheath.

6. The drug delivery system according to claim 2, characterized in that: The drug delivery system comprises a snap-on connection ring, one end of which is connected to the liquid collection port, and the other end of which is connected to the drug delivery tube.

7. The drug delivery system according to claim 1, characterized in that: The liquid collection port comprises a liquid collection hole, a connector, a puncture septum and a shell. The liquid collection hole is in fluid communication with the connector and is connected to the drug delivery tube via the connector. The shell accommodates the liquid collection hole, and the puncture septum covers the liquid collection hole for non-destructive needle puncture drug delivery.

8. The drug delivery system according to claim 1, characterized in that: The drug delivery system is inserted into the human body via the jugular vein, the liquid collection port is placed subcutaneously, and the positioning end of the drug delivery tube is positioned in the portal vein and abuts against the side wall of the portal vein.

9. The drug delivery system according to claim 1, characterized in that: The drug delivery system is delivered to the portal vein through a puncture system, which includes a guide wire, a puncture needle, a puncture catheter, a guide, a guide sleeve, an outer sheath, an outer sheath core and a dilator.

10. The drug delivery system according to claim 1, characterized in that: The inner and outer cavities of the drug delivery tube are both provided with anticoagulant coatings and the drug delivery tube is visible under X-rays.

Images